Posted by Michael Wonder on 29 Jun 2022
Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
22 June 2022 - Regulatory agencies have sought to speed up the review of new cancer medicines and reduce delays in approval between countries.
We examined trends in regulatory review times and association with clinical benefit for new cancer medicines in six jurisdictions: United States (FDA), European Union (EMA), Switzerland (Swissmedic), Japan (PMDA), Canada (Health Canada) and Australia (TGA).
